<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00036985</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069346</org_study_id>
    <secondary_id>CELSION-10200201</secondary_id>
    <secondary_id>OU-09533</secondary_id>
    <nct_id>NCT00036985</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy With or Without Microwave Thermotherapy Before Surgery in Treating Women With Locally Advanced Breast Cancer</brief_title>
  <official_title>A Randomized Pivotal Clinical Trial To Assess The Efficacy Of Pre-operative Focused Microwave Thermotherapy Treatment Combined With Pre-operative Chemotherapy For Cytoreduction Of Advanced Breast Cacer In Intact Breast</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celsion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Microwave thermotherapy kills tumor cells by heating them to&#xD;
      several degrees above body temperature. Combining chemotherapy with microwave thermotherapy&#xD;
      before surgery may shrink the tumor so that it can be removed during surgery.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to compare the effectiveness of combination chemotherapy&#xD;
      with or without microwave thermotherapy before surgery in treating women who have locally&#xD;
      advanced breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the safety and efficacy of neoadjuvant therapy comprising cytoreductive&#xD;
           doxorubicin and cyclophosphamide with or without focused microwave thermotherapy in&#xD;
           women with locally advanced breast cancer in an intact breast.&#xD;
&#xD;
        -  Evaluate percentage of patients who achieve at least 85% pathological cell death after&#xD;
           treatment with focused microwave thermotherapy.&#xD;
&#xD;
        -  Compare clear pathology tumor margins and reduction of second incision rates in patients&#xD;
           treated with these regimens.&#xD;
&#xD;
        -  Compare the amount of surgically removed breast and tumor tissue in patients treated&#xD;
           with these regimens.&#xD;
&#xD;
        -  Compare the measurement of the extent of tumor margins in patients treated with these&#xD;
           regimens.&#xD;
&#xD;
        -  Compare the reduction of tumor size in patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified&#xD;
      according to tumor size (T2 vs T3). Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive cyclophosphamide IV over 15 minutes and doxorubicin IV over 15&#xD;
           minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of&#xD;
           unacceptable toxicity.&#xD;
&#xD;
      During courses 1 and 2 only, patients undergo focused microwave thermotherapy on day 1 of&#xD;
      chemotherapy (or within 36 hours after chemotherapy). Patients undergo ultrasound-guided&#xD;
      placement of a microwave sensor and a temperature probe (before or after compression of the&#xD;
      breast) and external placement of 2 large opposing microwave emitters and up to 7 skin&#xD;
      temperature sensors on the compressed breast. Patients then receive focused microwave&#xD;
      thermotherapy that slowly heats the primary breast tumor and deep proximal breast tissue. In&#xD;
      the absence of any unacceptable toxicity, a target tumor temperature of 43-47Â° C is reached&#xD;
      and maintained for an equivalent thermal dose of 80-120 minutes.&#xD;
&#xD;
        -  Arm II: Patients receive chemotherapy only as in arm I. Within 60 days after completion&#xD;
           of thermochemotherapy or chemotherapy alone, patients in both arms undergo total&#xD;
           mastectomy, partial mastectomy, or other breast-conserving surgery, as appropriate. At&#xD;
           the discretion of the physician, beginning after completion of chemotherapy, patients in&#xD;
           both arms who are estrogen receptor positive may receive oral tamoxifen. Within 4 weeks&#xD;
           after completion of chemotherapy and surgery, eligible patients in both arms also&#xD;
           undergo radiotherapy to the breast and lymph nodes.&#xD;
&#xD;
      Patients are followed at 30 and 90 days.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 280-312 patients (140-156 per treatment arm) will be accrued&#xD;
      for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2001</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>thermal ablation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed locally advanced primary breast cancer&#xD;
&#xD;
               -  Stage III (T2-3, N2-3) disease&#xD;
&#xD;
               -  Diagnosis not made by lumpectomy or incisional biopsy&#xD;
&#xD;
          -  Currently a candidate for mastectomy and neoadjuvant chemotherapy&#xD;
&#xD;
          -  Primary tumor measurable by breast ultrasound and clinical exam&#xD;
&#xD;
          -  No bilateral breast cancer&#xD;
&#xD;
          -  No high probability for extensive intraductal in situ disease&#xD;
&#xD;
          -  No clinical fixation to the pectoralis major muscle or skin&#xD;
&#xD;
          -  No involvement of the nipple&#xD;
&#xD;
          -  No inflammatory breast cancer&#xD;
&#xD;
          -  No multicentric disease&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 6 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3 (no thrombocytopenia)&#xD;
&#xD;
          -  No bleeding disorders&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  PT and PTT less than 1.5 times normal&#xD;
&#xD;
          -  INR less than 1.5 times normal&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  Transaminases no greater than 2 times normal&#xD;
&#xD;
          -  No coagulopathy&#xD;
&#xD;
          -  No liver disease&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  BUN less than 30 mg/dL OR&#xD;
&#xD;
          -  Creatinine less than 1.9 mg/dL&#xD;
&#xD;
          -  No renal insufficiency&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No clinically significant heart disease&#xD;
&#xD;
          -  No pacemakers or defibrillators&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use 2 effective methods of contraception&#xD;
&#xD;
          -  No breast implants&#xD;
&#xD;
          -  No prior collagen vascular disease&#xD;
&#xD;
          -  No concurrent mental condition that would preclude study&#xD;
&#xD;
          -  No contraindications to chemotherapy&#xD;
&#xD;
          -  Able to tolerate prone position and breast compression&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No prior participation in this study&#xD;
&#xD;
          -  More than 30 days since participation in another clinical trial&#xD;
&#xD;
          -  No concurrent participation in another clinical trial&#xD;
&#xD;
          -  No concurrent anticoagulants&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William E. Gannon, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Celsion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Hospital Regional Cancer Center - Orange</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Breast Center of Coral Springs</name>
      <address>
        <city>Coral Springs</city>
        <state>Florida</state>
        <zip>33071</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma University Medical Center at University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mroz-Baier Breast Care Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Breast Care Specialists, P.C.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2004</verification_date>
  <study_first_submitted>May 13, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>December 18, 2013</last_update_submitted>
  <last_update_submitted_qc>December 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2013</last_update_posted>
  <keyword>stage IIIA breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

